Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.10.18
Views: 882

Prof Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy

Prof Paolo Ascierto speaks to ecancer at ESMO 2018 in Munich about the ILLUMINATE 301 trial, a phase 3 randomised comparison of ipilimumab alone versus IMO-2125 combined with ipilimumab in subjects with anti PD 1 refractory melanoma.

Prof Ascierto recaps the findings of phase 1 and the likely timeline of phase 3.

He also discusses the relevant findings of CheckMate 067, also presented at ESMO 2018, which uses ipilimumab combined with nivolumab.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation